Charleen Ml Chan Wah Hak

10PUBLICATIONS
80CO-AUTHORS
Molecular targetsChemotherapyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 30, 2026
"SMAC"-down for the apoptosis-restoring drug, Xevinapant: What does its story reveal?

|Mar 03, 2026
Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling.

Victoria Roulstone, Joan Kyula, Elizabeth Appleton

|Oct 22, 2025
Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer.

Charleen Chan Wah Hak, Emmanuel C Patin, Anton Patrikeev

|Jul 15, 2025
Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion.

Victoria Roulstone, Joan Kyula-Currie, James Wright

|Jul 08, 2025
The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models.

Joan Kyula-Currie, Victoria Roulstone, James Wright

|May 24, 2025
Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion.

Victoria Roulstone, Joan Kyula-Currie, James Wright

Pageof 2

Frequent Collaborators

8 joint publications

Kevin J Harrington

7 joint publications

Alan Melcher

6 joint publications

Antonio Rullan

6 joint publications

Emmanuel Christian Patin